Reports Q3 revenue $2.9M vs. $0.4M a year ago. As of September 30, 2022, Alaunos had approximately $37.8M in cash and cash equivalents and restricted cash of $13.9M. "Our team has worked diligently over the past year to transform our promising technology and scientific foundation into meaningful clinical progress. We were excited to present early data from our TCR-T Library Phase 1/2 trial at CICON, where we showed for the very first time, an objective clinical response in a solid tumor using a non-viral TCR-T cell therapy. These initial safety, persistence and efficacy data reinforce the promise of our Sleeping Beauty TCR-T cell therapy to safely achieve measurable regression in solid tumors, even at the lowest dose," commented CEO Kevin Boyle, Sr.. "In tandem, we have successfully doubled our manufacturing capacity. We look forward to dosing the next patient in our TCR-T Library Phase 1/2 Trial as well as filing an IND amendment to expand our TCR Library and enhance the speed and flexibility of our manufacturing process using cryopreserved cell products in the fourth quarter."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TCRT:
